Changing patterns of serum IL-6, IL-10, IL-23 and osteopontin levels in patients with smear-negative pulmonary tuberculosis and their clinical implication
10.16718/j.1009-7708.2016.03.019
- VernacularTitle:痰菌阴性肺结核患者血清白细胞介素-6、白细胞介素-10、白细胞介素-23、骨桥蛋白水平的动态变化及临床意义
- Author:
Xingliang HAO
- Publication Type:Journal Article
- Keywords:
smear-negative pulmonary tuberculosis;
interleukin-6;
interleukin-10;
interleukin-23;
osteopontin;
inlfammatory response
- From:
Chinese Journal of Infection and Chemotherapy
2016;16(3):359-362
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the changing patterns of serum IL-6, IL-10, IL-23 and osteopontin in patients with smear-negative pulmonary tuberculosis before and after treatment and their clinical implication.Methods A total of 43 patients with smear-negative pulmonary tuberculosis and 40 healthy controls were included in this study. Enzyme-linked immunosorbent assay (ELISA) was conducted to measure the levels of serum IL-6, IL-10, IL-23 and osteopontin in healthy individuals and patients before and after anti-tuberculosis treatment for 2, 4 and 6 months.Results The levels of serum IL-6, IL-10, IL-23 and osteopontin in patients with smear-negative pulmonary tuberculosis were signiifcantly higher than those in control group (P<0.05). After treatment for two months, the levels of serum IL-6, IL-10, IL-23 and osteopontin signiifcantly decreased in patients with smear-negative pulmonary tuberculosis (P<0.05). The serum IL-10 and osteopontin were nearly restored to normal levels in patients after four months treatment and there were no signiifcant difference compared with those in control group (P>0.05). The levels of serum IL-6 and IL-23 gradually decreased after treatment, and restored to normal at six months. There was no signiifcant difference compared with those in control group (P>0.05). Conclusions Serum IL-6, IL-10, IL-23 and osteopontin levels in patients with smear-negative pulmonary tuberculosis can be used as sensitive indicators for assessment of tuberculosis disease activity and therapeutic effect of anti-tuberculosis drugs.
